by GlobeNewsWire | Jun 7, 2016 | Globe Newswire
GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 07, 2016 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of...
by GlobeNewsWire | May 12, 2016 | Globe Newswire
Expanded inherited metabolic disease (IMD) portfolio; New programs address citrullinemia type 1, phenylketonuria (PKU), and Wilson disease Expect to file INDs for lead IMD product candidates, DTX301 for OTC deficiency and DTX401 for GSDIa, both in second half 2016;...
by GlobeNewsWire | May 12, 2016 | Globe Newswire
Enrollment Completed in 2nd Cohort of Ongoing Phase 1b Clinical Trial of VY-AADC01 in Advanced Parkinson’s Disease VY-AADC01 Interim Phase 1b Results to be Presented at 20th International Congress of Parkinson’s Disease & Movement Disorders in June 2016 CAMBRIDGE,...
by GlobeNewsWire | May 11, 2016 | Globe Newswire
CAMBRIDGE, Mass., May 11, 2016 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that company management...
by GlobeNewsWire | May 5, 2016 | Globe Newswire
Therapeutic Programs Address Citrullinemia Type 1, Phenylketonuria, and Wilson Disease Diseases Can Have Devastating Consequences for Patients and Families, with Few Effective Treatment Options Research Collaboration Positions Dimension as the Leading Innovative Gene...